A Phase 2/3 interventional study of M281 and Placebo in Warm Autoimmune Hemolytic Anemia, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 171 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one has the largest enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2019, is the only one in phase 2/3, and was the 13th registered.
103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.
Browse Anemia, Hemolytic, Autoimmune studies →4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Austria and 15 more countries
Ages 18+
Lakefront Biotherapeutics West LLC · Sites in United States, Australia
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Austria and 15 more countries
Ages 18–100
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Denmark, Germany and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 18 · Phase 3 9
First in 1997; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 23 across 78 interventional studies indexed under Anemia, Hemolytic, Autoimmune.
Median enrollment 24 across the 30 interventional studies, 429 across the 1 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 2 studies filed under Anemia, Hemolytic, Autoimmune — fewer than ten, so there is no comparison to draw.
1 of the studies in Anemia, Hemolytic, Autoimmune with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
The study consists of a 24-week double-blind, placebo control period, a 144-week open-label extension period and follow-up period of 8 weeks after last study drug administration. Eligible participants will be randomized to placebo or nipocalimab (2 dose levels) during the double-blind period and nipocalimab (2 dose levels) during the open-label extension period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive M281 administered every 4 weeks alternating with placebo every 4 weeks during the 24 weeks double-blind period.
Drug: M281 · Drug: Placebo
Participants will receive M281 administered every 2 weeks during the 24 weeks double-blind period.
Drug: M281
Participants will receive M281 matching placebo administered every 2 weeks during the 24 weeks double-blind period.
Drug: Placebo
Participants will receive M281 administered every 4 weeks during the 144 weeks open-label extension period.
Drug: M281
Participants will receive M281 administered every 2 weeks during the 144 weeks open-label extension period.
Drug: M281
M281 injection administered as intravenous infusion
Also known as: Nipocalimab, JNJ-80202135
Placebo administered as intravenous infusion
Percentage of Participants Achieving Durable Response of Improvement in Hemoglobin (Hgb)
Time frame: Up to Week 20 of the double-blind period
Change From Baseline in the Total Score From the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale at the Time of Durable Response
The FACIT-Fatigue is a self-administered 13-item questionnaire that assess patient-reported fatigue associated with chronic illness therapy. It assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in the Total Score From the FACIT-Fatigue Scale at the end of the Double-blind Period (Week 24)
The FACIT-Fatigue is a self-administered 13-item questionnaire that assess patient-reported fatigue associated with chronic illness therapy. It assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline (Day 1, Week 0) through Week 24 of the double-blind period
Change from Baseline in Average Daily Dose of Prednisone or Equivalent
Change from baseline in average daily dose of prednisone or equivalent at week 24 among participants on prednisone or equivalent at baseline will be reported.
Time frame: Baseline (Day 1, Week 0) and at Week 24
Number of Participants That Simultaneously Attain Normal Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin Levels at a Minimum of 3 Consecutive Visits After Baseline
Time frame: Baseline (Day 1, Week 0) through Week 24
Percentage of Participants who Experience at Least a 2 g/dL Increase in Hgb From Baseline and Normalization of Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin at any Time During the Study
Time frame: Baseline (Day 1, Week 0) through Week 24
Percentage of Participants who Experience at Least a 2 g/dL Increase in Hgb From Baseline and Normalization of Lactate Dehydrogenase, Haptoglobin, and Indirect Bilirubin at 3 Consecutive Visits
Time frame: Baseline (Day 1, Week 0) through Week 24
Percentage of Participants who Achieve the Durable Response in Improvement of Hgb During the Double-blind Period and Maintain that Response for Up to 24 Weeks, Without the Need of Rescue Therapy
Percentage of participants who achieve the durable response in improvement of Hgb during the double-blind period and maintain that response for up to 24 weeks, without the need of rescue therapy will be reported.
Time frame: Up to 24 weeks
Change From Baseline in Hgb Concentration
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Reticulocyte Count
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Hemolytic Marker - Lactate Dehydrogenase
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Hemolytic Marker - Haptoglobin
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Hemolytic Marker - Indirect Bilirubin
Time frame: Baseline (Day 1, Week 0) through Week 24
Time to Hgb Response
Time frame: Baseline (Day 1, Week 0) through Week 24
Mean Time During Which the Primary Endpoint is Maintained
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in the Total Score, Item Scores, and Impact and Experience Domains From the FACIT-Fatigue Scale
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline (Day 1, Week 0) through Week 24 of the double-blind period
Change From Baseline in EuroQol 5-dimension 5-level ( EQ-5D-5L) Scale Score
The EQ-5D-5L quality of life questionnaire will be used to assess health related quality of life status. The 5 dimensions are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; each dimension is rated by the patient on a 5 level scale (no problems, slight problems, moderate problems, severe problems, extreme problems).
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Medical Outcomes Study Short Form 36 Item Health Survey Version 2 Acute (SF-36v2) Score
The SF-36v2 will be used to assess general quality of life. The 36 items on the SF-36 health survey encompass the following 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 8 domains can be aggregated into 2 summary scales that reflect physical and mental health: a physical component summary (PCS) and a mental component summary (MCS). Responses to all items are rated on a 3-, 5- or 6-point Likert scale. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline (Day 1, Week 0) through Week 24
Change From Baseline in Patient Global Impression of Severity (PGIS)
The PGIS will be used to assess the severity of warm autoimmune hemolytic anemia (wAIHA) fatigue symptoms. The PGIS is a 5-point response scale. Participant will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.
Time frame: Baseline (Day 1, Week 0) through Week 24
Patient-reported Status As Assessed by Patient Global Impression of Change (PGIC) Scale Score
The PGIC will assess if there has been an improvement or decline in patient-reported status since the beginning of the treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.
Time frame: At Week 24
Hgb Range at Steady State
It will be estimated using a model-based longitudinal analysis of Hgb/hemolysis parameters in relationship to IgG level and dose regimen.
Time frame: Baseline (Day 1, Week 0) through Week 24
Absolute Change from Baseline in Average Daily Dose of Prednisone or Equivalent
Absolute change from baseline in average daily dose of prednisone or equivalent at Week 24 among all participants will be reported.
Time frame: Baseline (Day 1, Week 0) and at Week 24
Percentage of participants who Achieve Corticosteroid Reduction to less than or equal to (<=) 7.5 milligrams per day (mg/day) of Oral Prednisone (or Equivalent), Among Participants with Prednisone or Equivalent greater than (>) 7.5 mg/day at Baseline
Percentage of participants who achieve corticosteroid reduction to \<= 7.5 mg/day of oral prednisone (or equivalent) at Week 24 of the double-blind period, among participants with prednisone or equivalent \>7.5 mg/day at baseline will be reported.
Time frame: At Week 24
Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.
Plan to share: No
Ran from Aug 2019 to primary completion in Feb 2025, 65 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nipocalimab
Anemia, Hemolytic, Autoimmune →
Janssen Research & Development, LLC →